S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:ATHX

Athersys (ATHX) Stock Forecast, Price & News

$0.99
0.00 (-0.40%)
(As of 04:16 PM ET)
Compare
Today's Range
$0.95
$0.99
50-Day Range
$0.77
$1.45
52-Week Range
$0.50
$10.50
Volume
55,536 shs
Average Volume
230,422 shs
Market Capitalization
$18.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Athersys MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
455.6% Upside
$5.50 Price Target
Short Interest
Healthy
4.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Athersys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

820th out of 1,009 stocks

Pharmaceutical Preparations Industry

412th out of 494 stocks


ATHX stock logo

About Athersys (NASDAQ:ATHX) Stock

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Stock News Headlines

Athersys Restructures Debt with Supplier
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Athersys (NASDAQ:ATHX) Upgraded by StockNews.com to Hold
Athersys, Inc. (NASDAQ:ATHX) Short Interest Update
Athersys (NASDAQ:ATHX) Downgraded by StockNews.com to Sell
Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
Athersys Provides MultiStem Clinical Update
See More Headlines
Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Company Calendar

Last Earnings
3/31/2023
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
104
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+456.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-72,530,000.00
Net Margins
-1,362.14%
Pretax Margin
-2,408.99%

Debt

Sales & Book Value

Annual Sales
$5.32 million
Book Value
($1.33) per share

Miscellaneous

Free Float
16,714,000
Market Cap
$18.23 million
Optionable
Optionable
Beta
-0.71

Social Links


Key Executives

  • Daniel A. Camardo
    Chief Executive Officer, Secretary, Director & CAO
  • Maia A. Hansen
    Chief Operating Officer
  • Kasey Rosado
    Chief Financial Officer
  • Rakesh Ramachandran
    Head-Information Technology & Communications
  • Manal Morsy
    Executive VP & Head-Global Regulatory Affairs













ATHX Stock - Frequently Asked Questions

Should I buy or sell Athersys stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares.
View ATHX analyst ratings
or view top-rated stocks.

What is Athersys' stock price forecast for 2023?

1 analysts have issued 12-month target prices for Athersys' shares. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 456.6% from the stock's current price.
View analysts price targets for ATHX
or view top-rated stocks among Wall Street analysts.

How have ATHX shares performed in 2023?

Athersys' stock was trading at $0.84 on January 1st, 2023. Since then, ATHX stock has increased by 17.6% and is now trading at $0.9881.
View the best growth stocks for 2023 here
.

When is Athersys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ATHX earnings forecast
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings data on Friday, March, 31st. The biopharmaceutical company reported ($0.83) EPS for the quarter. The biopharmaceutical company had revenue of $0.03 million for the quarter.

When did Athersys' stock split?

Shares of Athersys reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?
What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a number of institutional and retail investors. Top institutional investors include Vahanian & Associates Financial Planning Inc. (4.44%), State Street Corp (0.23%), CIBC Asset Management Inc (0.20%), Group One Trading L.P. (0.00%), Simplicity Solutions LLC (0.17%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Daniel A Camardo, Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends
.

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $0.99.

How much money does Athersys make?

Athersys (NASDAQ:ATHX) has a market capitalization of $18.23 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

How many employees does Athersys have?

The company employs 104 workers across the globe.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.

This page (NASDAQ:ATHX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -